← Back to patent-cliff list
BRM-421
Tier C — Watch / tradeBRM-421
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PEDF
Indications (approved)：Dry eye syndrome, Keratoconjunctivitis sicca, Dry eye disease
Regional status
US
Phase III
2020-01-15
EU
-
China
Phase I
2023-04-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BRM-421?
Approved indications include: Dry eye syndrome, Keratoconjunctivitis sicca, Dry eye disease.
When does the BRM-421 patent expire?
No public expiry year is available for BRM-421 yet; this page updates once verified.
How do I get a quote for BRM-421 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07